Poniard Pharmaceuticals, Inc. (Public, NASDAQ:PARD) drug candidate - PND 1186 is relatively undiscussed in the investment community. Yet to be published in the May Journal of Cancer and Biology Therapy.
TapeBeat.Com, the news and research portal for the serious investor is proud to present information regarding Poniard Pharmaceuticals, Inc., (Public, NASDAQ:PARD). Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. PARD received favorable clinical results in a phase II study on Picoplatin and much attention for the company in general.
Relativley unknown to investors is PARD’s PMD 1186 drug candidate. Cancer and Biology Therapy’s May issue has two abstracts regarding PND 1186, and an article appearing with comments from Michael D. Schaller, Department of Biochemistry, West Virginia University and Steven M. Frisch, Mary Babb Randolph Cancer Center and Department of Biochemistry, West Virginia University.
Although set to publish in May the abstracts are available now at landesbioscience.com.
This link is entitled:
"PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments".
This link is entitled:
"Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models"There is also an article with comments, as mentioned above that is yet to be released online.
It seems noteworthy that comments by both a Senior Rodman Analyst and an IPO Attorney Watchdog have been made within the last week while this newer information is pending for publication. The positive comments made by IP Watchdog, Gene Quinn at ipwatchdog.com are especially insightful and can be viewed here.
How significant this drug candidate is will be discussed by the professional community now that the information is presented in a professional journal. How this information effects the bottom line for PARD will be arguably discussed by investors, traders and those that take ‘short positions’ in the stock of PARD.
An article appeared in biomedreports written by Rodman & Renshaw’s Managing Director and Senior Biotechnology Analyst, Simos Simeonidis, Ph.D, who among other things stated that “Yes, we believe that there is a pharma company out there that likes picoplatin.” Rodman & Renshaw’s website states that Since 2003, Rodman has completed over 230 transactions and raised over $3.7 billion for healthcare companies. We encourage you to read these articles at biomedreports.com and ipwatchdog.com for a better contextual understanding and also subscribe to biomedreports.com FDA calendar, which is a useful tool.
Remember where you heard it first. For futher information, the links mentioned, or to sign up for advance alerts visit us at TapeBeat.Com.
Philip Runfeldt
Position: Long PARD
By viewing this information you agree to the disclaimer found on the website. The opinions expressed are that of the individual contributor(s). Neither the company releasing this information, nor the contributor(s) are associated with the company(s) mentioned or acting on their behalf. None are certified financial advisor(s) or professional analysts. This is not a solicitation to trade any security or a recommendation. Please do your own due diligence as, trading in equities may occur loss of your principal.
